BridgeBio price target raised to $95 from $70 at Cantor Fitzgerald

Cantor Fitzgerald analyst Josh Schimmer raised the firm’s price target on BridgeBio (BBIO) to $95 from $70 and keeps an Overweight rating on the shares. BridgeBio reported Q4 earnings, including noting that 1,028 Attruby prescriptions have been written as of February 17, implying about 120 new prescriptions per week since January 13, a significant acceleration that reflects larger treatment centers coming on line, the analyst tells investors in a research note. With 2,000-3,000 newly treated transthyretin amyloid cardiomyopathy patients per quarter, the firm says BridgeBio appears to have captured significant market share already.